EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Autologous Serum from Sjögren’s Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy

Guanghong Chu, Jiao Wang, Zihuan Wang, Xiaoyu Cai, Siyuan Shi, Qiping Qing, Yu Zhong, Qi Zhang

Journal of Ocular Pharmacology and Therapeutics · 2025-09-01 · 41 (7) · 397-407

DOI: 10.1089/jop.2025.0025 ↗
AbstractBibliografische Angaben

Abstract

Purpose: To investigate the role of autologous serum (AS) in alleviating hyperosmolarity-induced corneal epitheliopathy via the ferroptosis pathway. Methods: AS was extracted and prepared from patients with Sjögren’s syndrome. An in vitro hyperosmotic dry eye model was established by exposing HCE-T cells to 90 mM NaCl, followed by treatment with AS or ferroptosis inhibitors. Protein expression was analyzed using Western blotting. Intracellular Fe 2+ and reactive oxygen species (ROS) levels were determined by FerroOrange and 2’,7’-Dichlorodihydrofluorescein diacetate (H2DCFDA) fluorescent probes, and cellular malondialdehyde and glutathione levels were measured using kits. Transmission electron microscopy was utilized to examine mitochondrial ultrastructure. Results: Under hyperosmotic conditions, HCE-T cells exhibited increased lipid peroxidation and iron accumulation, accompanied by significant alterations in the expression of ferroptosis-related markers and characteristic changes in mitochondrial morphology, which indicated the induction of ferroptosis. Among the tested concentrations, 20% and 50% AS demonstrated notable therapeutic effects, significantly enhancing cell viability and migration, reducing ROS and Fe 2+ levels, and alleviating mitochondrial damage. Furthermore, AS effectively inhibited ferroptosis through the Xc − /glutathione peroxidase 4 (GPX4) pathway. Conclusions: AS reduced lipid peroxidation levels in HCE-T cells under hyperosmolarity and inhibited ferroptosis through the Xc − /GPX4 pathway.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →